Transcode Therapeutics shares are trading lower by 11% to 34 cents Monday afternoon. The company announced its Board's ...
TransCode Therapeutics (NASDAQ:RNAZ) will execute its previously announced 1-for-33 reverse stock split on Dec. 4, 2024. The company’s common stock is expected to begin trading on a split-adjusted ...
As previously announced, the 1-for-33 reverse stock split will automatically convert thirty-three current shares of TransCode’s common stock into one new share of common stock. No fractional shares ...
TransCode Therapeutics ( (RNAZ) ) has provided an update.
TransCode Therapeutics (RNAZ) has entered into a securities purchase agreement with certain institutional investors. The aggregate gross cash proceeds are expected to be approximately $8M before ...
TransCode Therapeutics, Inc. BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using ...
BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company: Dear Shareholders ...
TransCode Therapeutics shares are trading lower by 16% during Monday's session. The company announced a 1-for-33 reverse ...
In connection with the reverse stock split, the Company's CUSIP number will change to 89357L402 as of 12:01 a.m. Eastern Standard Time on December 4, 2024. About TransCode Therapeutics TransCode ...
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to ...
BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to ...